These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1170 related articles for article (PubMed ID: 27061303)

  • 41. The Calreticulin gene and myeloproliferative neoplasms.
    Clinton A; McMullin MF
    J Clin Pathol; 2016 Oct; 69(10):841-5. PubMed ID: 27354406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Expression level of Wilms' tumor 1 gene and its correlation with clinical features in patients with myeloproliferative neoplasms].
    Liu C; Wu SY; Zhang AB; Luo P; Zhou Y; Liu Y; Zuo XL
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3658-3664. PubMed ID: 38018065
    [No Abstract]   [Full Text] [Related]  

  • 46. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
    Maddali M; Kulkarni UP; Ravindra N; Arunachalam AK; Venkatraman A; Lionel S; Manipadam MT; Devasia AJ; Korula A; Fouzia NA; Abraham A; Srivastava A; George B; Balasubramanian P; Mathews V
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):13-20. PubMed ID: 33789164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
    Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
    Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
    Tanaka M; Yujiri T; Ito S; Okayama N; Takahashi T; Shinohara K; Azuno Y; Nawata R; Hinoda Y; Tanizawa Y
    Int J Hematol; 2013 Mar; 97(3):409-13. PubMed ID: 23430670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
    Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
    Leuk Res; 2018 Feb; 65():42-48. PubMed ID: 29306106
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
    Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
    Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).
    Zulkeflee RH; Zulkafli Z; Johan MF; Husin A; Islam MA; Hassan R
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
    Tang Q; Zhang XW; Xia L; Jiang NK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.
    Ngoc NT; Hau BB; Vuong NB; Xuan NT
    Mol Genet Genomic Med; 2022 Oct; 10(10):e2044. PubMed ID: 35996819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
    Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
    J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.
    Rumi E; Harutyunyan AS; Pietra D; Milosevic JD; Casetti IC; Bellini M; Them NC; Cavalloni C; Ferretti VV; Milanesi C; Berg T; Sant'Antonio E; Boveri E; Pascutto C; Astori C; Kralovics R; Cazzola M;
    Blood; 2014 Apr; 123(15):2416-9. PubMed ID: 24553179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation.
    Haunstrup LM; Ebbesen LH; Hansen M; Severinsen MT; Aggerholm A
    Exp Hematol; 2018 Dec; 68():62-65. PubMed ID: 30292681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
    Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J
    Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.